Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Diagnostics | Free Full-Text | Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Siba El Hussein, MD on Twitter: "Daratumumab, an anti-CD38 IgG Kappa antibody, can cause light chain restriction in hematogones, proposed mechanism shown in video below: #hemepath #pathtwitter #mmsm @KirillLyapichev @sanamloghavi @KMirza @Xiaoqiong_Wang @
Daratumumab for Severe Refractory Proliferative Glomerulonephritis with Monoclonal Immune Deposits (PGNMID). - ATC Abstracts
HCP Website | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay - ScienceDirect
How to get clearer test results on monoclonal antibodies
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference
Electrophoretic patterns post daratumumab - Joanna Sheldon, Rachel D Wheeler, Ray Powles, 2018
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease | Leukemia
Everything you need to know about Daratumumab and Multiple Myeloma - Curetalks
Daratumumab - wikidoc
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study - Roy Vitkon, Dan Netanely, Shai Levi, Tomer
DARZALEX® (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay. | Semantic Scholar
Columba Trial | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion - ScienceDirect
Frontiers | Daratumumab for the Treatment of Multiple Myeloma
Detection of daratumumab and nivolumab by serum immunofixation... | Download Scientific Diagram
Schematic presentation of double IFE Hydrashift Assay. (A) The... | Download Scientific Diagram
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
